# VictORION-INCLUSION: Evaluating Inclisiran for Cholesterol Managment in Heart Disease

Study · id `cardio:ct-nct06249165` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT06249165](<https://clinicaltrials.gov/study/NCT06249165>), retrieved 31 October 2026. No person wrote or checked this page.

Also called: NCT06249165

Browse, organ or system: Blood vessels; Metabolism  
Browse, condition area: Risk and prevention; Coronary and vascular disease; Diabetes and metabolic disease  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is active, not recruiting. It enrolled 130 participants.

## Technical summary

Registry record NCT06249165. Randomized; no masking; primary purpose treatment. Start 2024-12-16 (actual); primary completion 2026-12-31 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 130 participants (enrolled count; ClinicalTrials.gov record NCT06249165, source copy `cardio:ctgov-nct06249165-2026-07-29`, retrieved 2026-10-31)
- Started: 2024-12-16 (actual) (ClinicalTrials.gov record NCT06249165, source copy `cardio:ctgov-nct06249165-2026-07-29`, retrieved 2026-10-31)
- Primary completion: 2026-12-31 (anticipated) (ClinicalTrials.gov record NCT06249165, source copy `cardio:ctgov-nct06249165-2026-07-29`, retrieved 2026-10-31)
- Completion: 2027-02-28 (anticipated) (ClinicalTrials.gov record NCT06249165, source copy `cardio:ctgov-nct06249165-2026-07-29`, retrieved 2026-10-31)
- Countries: United States (ClinicalTrials.gov record NCT06249165, source copy `cardio:ctgov-nct06249165-2026-07-29`, retrieved 2026-10-31)
- Care setting: Not reported
- Registry status: "ACTIVE\_NOT\_RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct06249165-2026-07-29`, retrieved 2026-10-31)

## The registry's words

- Brief title: VictORION-INCLUSION: Evaluating Inclisiran for Cholesterol Managment in Heart Disease
- Acronym: V-INCLUSION
- Condition: Atherosclerotic Cardiovascular Disease
- Intervention (Drug): Inclisiran
- Lead sponsor: Duke University
- Lead sponsor class: OTHER
- Collaborator: Novartis Pharmaceuticals
- Collaborator class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Atherosclerosis (`cardio:atherosclerosis`)
- Registry condition terms include this condition: Dyslipidemia (`cardio:dyslipidemia`)
- Registry condition terms include this condition: High cholesterol (hypercholesterolemia) (`cardio:hypercholesterolemia`)
- Registry intervention name matches this record: Inclisiran (`cardio:inclisiran`)
- Registry lists this organization as the lead sponsor: Duke University (`cardio:org-duke-university`)
- Registry lists this organization as a collaborator: Novartis (`cardio:novartis`)

## Provenance

Content hash: 8ab2303f1e6397b10ce27199710f0e3008d84bc0a3e236256ca5cdc9d1c660e6
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
